Recorded Presentations from the NCCN 2023 Oncology Fellows Program: New Horizons in Quality Cancer Care

The goal of this program is to ensure that oncology fellows and other members of the interprofessional oncology care team have the knowledge and skills necessary to apply the standards of care to their practice and health care setting for patients with cancer.

Target Audience

This program is designed to meet the educational needs of physicians, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

  • Evaluate advances in the management of patients with cancer and key updates in the NCCN Guidelines® and apply appropriate treatment and supportive care strategies to optimize patient education and care. 
  • Review issues related to the following topics: An Exploration of Oncology Professions Beyond Research and Clinical Practice; How to Optimize Systemic Therapy Outside of the Cancer Center: Best Practices for Managing Anticancer Therapies; The Art of Creating and Sustaining Interprofessional Teams to Provide Comprehensive Care Throughout the Patient Journey; Team-Based Management of Immunotherapy-Related Toxicities; and Management of Central Nervous System Metastases.
Additional information
Supporters: 

This activity is supported by educational grants from AstraZeneca; Coherus BioSciences; Genentech, a member of the Roche Group; Gilead Sciences,Inc.; GSK; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Novartis; and NOVOCURE. This activity is supported by an independent educational grant from Bristol Myers Squibb. This educational activity is supported by a medical education grant from Exelixis, Inc. This activity is supported by a grant from Pfizer Inc.

Course summary
Course opens: 
05/15/2023
Course expires: 
03/01/2024
Cost:
$0.00

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty and Moderator Disclosures

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Gwen Darien
Susan E. Franco, RN, BSN, OCN
Wui-Jin Koh, MD
Yehoda M. Martei, MD, MSCE
Barbara L. McAneny, MD
Bryan J. Schneider, MD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Jonathan D. Cheng, MD
Bristol-Myers Squibb Company: Equity Interest/Stock Options; Salary 
Merck & Co., Inc.: Equity Interest/Stock Options

Robert L. Coleman, MD
AbbVie, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support; Honoraria; Scientific Advisor 
Caris Life Sciences: Scientific Advisor
Clovis Oncology: Grant/Research Support 
Eisai Inc.: Scientific Advisor
Genentech, Inc.: Grant/Research Support 
GlaxoSmithKline: Consulting Fee; Scientific Advisor
ImmunoGen, Inc.: Consulting Fee; Grant/Research Support; Honoraria; Scientific Advisor 
Merck & Co., Inc.: Grant/Research Support; Scientific Advisor
Novocure: Grant/Research Support; Scientific Advisor 
SeaGen: Grant/Research Support; Scientific Advisor

Crystal S. Denlinger, MD
Agios, Inc.: Grant/Research Support 
Amgen Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support 
BeiGene: Scientific Advisor; Grant/Research Support
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support 
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Grant/Research Support 
Genmab: Grant/Research Support 
MacroGenics: Grant/Research Support 
MedImmune Inc: Grant/Research Support 
Merck & Co., Inc.: Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support 
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor
Zymeworks: Scientific Advisor; Grant/Research Support

Timothy Kubal, MD, MBA
Apellis Pharmaceuticals: Consulting Fee

L. Burt Nabors, MD
Chimerix: Scientific Advisor

Bianca D. Santomasso, MD, PhD
Bristol-Myers Squibb Company: Consulting Fee 
Gilead Sciences, Inc.: Consulting Fee
IN8BIO, Inc.: Scientific Advisor 
Incyte Corporation: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee 
Legend Biotech: Consulting Fee

B. Douglas Smith, MD
Bristol-Myers Squibb Company: Consulting Fee 
Celgene Corporation: Consulting Fee 
Celularity Inc.: Consulting Fee
Jubilant Pharma Limited: Scientific Advisor
Novartis Pharmaceuticals Corporation: Consulting Fee 
Pfizer Inc.: Consulting Fee
Servier Pharmaceuticals LLC: Consulting Fee

Yinghong (Mimi) Wang, MD, PhD 
AzurRx BioPharma: Consulting Fee 
Ilya Pharma AB: Consulting Fee 
MabQuest SA: Scientific Advisor 
Sanarentero, LLC: Consulting Fee
Sorriso Pharmaceuticals: Consulting Fee 
Springer: Royalty Income

NCCN Staff Disclosures

The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Crystal S. Denlinger, MD
Agios, Inc.: Grant/Research Support 
Amgen Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support 
BeiGene: Scientific Advisor; Grant/Research Support
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support 
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Grant/Research Support 
Genmab: Grant/Research Support 
MacroGenics: Grant/Research Support 
MedImmune Inc: Grant/Research Support 
Merck & Co., Inc.: Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support 
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor
Zymeworks: Scientific Advisor; Grant/Research Support

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This program has been approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, and other health care professionals. Complete accreditation information is provided before each individual educational activity.

 
Status
Price
Title
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing